We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




PCR Screening and Typing, Toolset Expanded for Ebolavirus

By LabMedica International staff writers
Posted on 19 Aug 2014
Print article
Image: Colorized transmission electron micrograph (TEM) revealing some of the ultrastructural morphology of an Ebolavirus virion (Image courtesy of Cynthia Goldsmith and the US Centers for Disease Control and Prevention (USA; CDC ref# PHIL 1832), via Wikimedia Commons).
Image: Colorized transmission electron micrograph (TEM) revealing some of the ultrastructural morphology of an Ebolavirus virion (Image courtesy of Cynthia Goldsmith and the US Centers for Disease Control and Prevention (USA; CDC ref# PHIL 1832), via Wikimedia Commons).
A new real-time polymerase chain reaction (RT-PCR)-based assay for identification of the five Ebolavirus species and Marburgvirus has been added to the Ebolavirus diagnostics toolset.

altona Diagnostics, GmbH (Hamburg, Germany), focused on the development, approval, manufacturing, and marketing of molecular diagnostic test systems for the detection and quantification of pathogens, has added a real-time RT-PCR-based assay, the RealStar Filovirus type RT-PCR kit, for identification of the five known Ebolavirus species and of Marburgvirus to their product portfolio. In addition to other activities, altona Diagnostics was also among the first to make reliable diagnostic kits commercially available during outbreaks for severe acute respiratory syndrome (SARS), avian Flu, swine Flu, and enterohemorrhagic Escherichia coli (EHEC).

Together with their already existing RealStar Filovirus Screen RT-PCR kit for first-line analysis, which is currently being used in the epidemic epicenter in West-Africa by the European Mobile Laboratory, altona Diagnostics now offers a comprehensive assay family for the detection and characterization of filovirus RNA from human sample material. While the screen kit detects all five Ebolavirus species without differentiation, as well as Marburgvirus, the typing kit is meant to be used as a second-line assay for confirmation of positive results and to distinguish between the five Ebolavirus species as well as Marburgvirus. Both kits are compatible with various real-time PCR platforms.

“For us, in the current situation during this epidemic outbreak, it´s more relevant that we were able to come up with a ready-to-use first-line test kit for filoviruses , which is now used in Guinea and Nigeria to identify infected patients and which is stocked by several European reference institutions under their preparedness plans,” said Dr. Markus Hess, chief scientific officer of altona Diagnostics, “The characterization of a positive sample by using the RealStar Filovirus type RT-PCR kit for Ebola and Marburgvirus is more of epidemiological and scientific importance.”

The ready-to-use real-time PCR kits for screening and typing of filoviruses are available as research use only reagents, currently. The In-Vitro Diagnostic (IVD) CE-marked version of the RealStar Filovirus Screen RT-PCR Kit will be available in September 2014.

Related Links:

altona Diagnostics
RealStar Filovirus RT-PCR kits


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.